Last Updated : October 10, 2024
Details
| Call for patient/clinician input open | 30-Aug-23 |
|---|---|
| Call for patient/clinician input closed | 24-Oct-23 |
| Clarification: - Patient input submission received from Arthritis Consumer Experts, Canadian Spondyloarthritis Association (CSA),Canadian Arthritis Patient Alliance (CAPA),Arthritis Society Canada (ASC) and Creaky Joints (CJ) | |
| Submission received | 19-Oct-23 |
| Submission accepted | 02-Nov-23 |
| Review initiated | 03-Nov-23 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 30-Jan-24 |
| Deadline for sponsors comments | 08-Feb-24 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 14-Mar-24 |
| Expert committee meeting (initial) | 27-Mar-24 |
| Draft recommendation issued to sponsor | 10-Apr-24 |
| Draft recommendation posted for stakeholder feedback | 18-Apr-24 |
| End of feedback period | 03-May-24 |
| Final recommendation issued to sponsor and drug plans | 16-May-24 |
| Final recommendation posted | 04-Jun-24 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 31-May-24 |
| Canada's Drug Agency review report(s) posted | 10-Oct-24 |